The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov

BACKGROUND: As medication expenditures rise, payers are increasingly demanding evidence of economic value for new medications. The 2015 Professional Society for Health Economics and Outcomes Research (ISPOR) Task Force on Cost-Effectiveness Analysis Alongside Clinical Trials noted that clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitchell, Jordan M., Patterson, Julie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391117/
https://www.ncbi.nlm.nih.gov/pubmed/32223593
http://dx.doi.org/10.18553/jmcp.2020.26.4.386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391117/
https://www.ncbi.nlm.nih.gov/pubmed/32223593
http://dx.doi.org/10.18553/jmcp.2020.26.4.386

Ejemplares similares